仑伐替尼联合帕博利珠单抗治疗复发性子宫内膜癌的不良事件与肿瘤学结局
本研究回顾性分析了43例复发性子宫内膜癌患者,接受仑伐替尼联合帕博利珠单抗治疗,最常见组织学类型为浆液性(35%)、子宫内膜样(23%)和癌肉瘤(21%)。36例(84%)发生≥3级不良事件,标准剂量组观察到的无进展生存期显著短于减量组(P=0.02),但缓解持续时间(P=0.09)和总生存期(P=0.27)无差异。
要点
- 36例(84%)发生≥3级不良事件,常见为高血压、体重减轻、贫血、疲乏和血小板减少。
- 24例(56%)需至少1次仑伐替尼减量,3例(7%)因不耐受或不良事件停用仑伐替尼。
- 标准剂量组观察到的无进展生存期显著短于减量组(P=0.02),但缓解持续时间和总生存期无差异。
核心结论
- 在临床实践中,仑伐替尼联合帕博利珠单抗相关不良事件常见,与Study 309/KEYNOTE-775研究结果相当。
- 不良事件在仑伐替尼不同起始剂量间相似。
- 复发性子宫内膜癌中可能需要进一步开展仑伐替尼联合帕博利珠单抗的剂量优化研究。
- 临床试验数据仍是指导仑伐替尼起始剂量的金标准。
研究设计与样本
- 回顾性研究,纳入2019年10月1日至2021年11月30日在本机构接受仑伐替尼联合帕博利珠单抗治疗的复发性子宫内膜癌患者43例。
- 仑伐替尼起始剂量定义为标准剂量(20 mg)或减量(10 mg/14 mg)。
- 不良事件通过病历回顾手动提取,并按常见不良事件评价标准(CTCAE)5.0版分级。
- 分析无进展生存期(PFS)、总生存期(OS)和缓解持续时间(DOR)。
主要发现
- 中位年龄67岁(范围54-85岁)。
- 最常见组织学类型为浆液性(35%)、子宫内膜样(23%)和癌肉瘤(21%)。
- 仑伐替尼起始剂量为10 mg(n=10)、14 mg(n=10)和20 mg(n=23)。
- 中位接受周期数为8(范围1-42)。
- 24例(56%)需至少1次仑伐替尼减量;3例(7%)停用仑伐替尼,1例(2%)因不耐受或不良事件停用帕博利珠单抗。
关键数值与推荐
- 仑伐替尼起始剂量:标准剂量20 mg,减量10 mg或14 mg。
- 不良事件分级采用CTCAE 5.0版。
临床怎么用
- 在临床实践中,仑伐替尼联合帕博利珠单抗相关不良事件常见,与Study 309/KEYNOTE-775研究结果相当。
- 不良事件在仑伐替尼不同起始剂量间相似。
- 复发性子宫内膜癌中可能需要进一步开展剂量优化研究。
- 临床试验数据仍是指导仑伐替尼起始剂量的金标准。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate adverse events (AEs) of combination lenvatinib plus pembrolizumab for the treatment of recurrent endometrial cancer (EC) and to assess outcomes by lenvatinib starting dose. METHODS: We retrospectively reviewed patients with recurrent EC treated with lenvatinib plus pembrolizumab at our institution between 10/1/2019-11/30/2021. Starting dose of lenvatinib was defined as standard (20 mg) or reduced (10 mg/14 mg). AEs were manually extracted through chart review and graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. PFS, overall survival (OS), and duration of response (DOR) were analyzed. RESULTS: Forty-three patients were identified; median age was 67 years (range, 54-85). The most common histologies were serous (35%), endometrioid (23%), and carcinosarcoma (21%). Starting lenvatinib doses were 10 mg (n = 10), 14 mg (n = 10), and 20 mg (n = 23). Median number of cycles received was 8 (range, 1-42). Twenty-four patients (56%) required ≥1 lenvatinib dose reduction; 3 (7%) discontinued lenvatinib, and 1 (2%) discontinued pembrolizumab for intolerance or AE. Thirty-six patients (84%) experienced grade ≥ 3 AEs; hypertension, weight loss, anemia, fatigue, and thrombocytopenia were most common. The standard dose group experienced significantly shorter observed PFS vs the reduced dose group (P = .02). There was no difference in DOR (P = .09) or OS (P = .27) between the groups. CONCLUSION: In clinical practice, AEs associated with combination lenvatinib plus pembrolizumab were common and comparable to Study 309/KEYNOTE-775 findings. AEs were similar regardless of starting lenvatinib dose. Further dose optimization studies of lenvatinib plus pembrolizumab may be indicated in recurrent EC. Clinical trial data remain the gold standard to guide starting lenvatinib dosing.
引用
- Zammarrelli WA, Ma W, Espino K, et al. Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer. Gynecol Oncol. 2023. PMID: 37748268. doi:10.1016/j.ygyno.2023.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。